Comparative Study of rhPDGF-BB Plus Equine-Derived Bone Matrix Versus rhPDGF-BB Plus β-TCP in the Treatment of Periodontal Defects

Lee, Ji-Young; Na, Hei-Jin; Kim, Hyun‐Min; Lee, Sang Cheol; Lee, Jue‐Yeon; Chung, Chong-Pyoung; Seol, Yang‐Jo; Park, Yoon Jeong

doi:10.11607/prd.3401

Cited by 11 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One‐hundred and twenty‐two treatment arms employed EMD 13 , 18,19,39,49,50,67,70,73,75–77,79,82,84–86,89,90,93,94,96–99,102,105–109 , 112–116,121–123,125,126,130,136–138,140–142,146,151,153,156–158,160,167–169,175 , 177,178,180,182–195,200–202,205–207,209–212 ,. 12 used rhPDGF‐BB 17,129,133,139,148,152,155,181 , 43 included PRF 19,71,72,74,78,80,81,83 , 88,91,92,103,110,115,120,131,144,145,149,150,154,162–165,170–174,196–198,203,204 , and 31 used PRP 68,87,95,100,101,117–119,124,127,128,132,134,135,143,147 , 159,161,166,173,174,179,199 . All in all 28 treatment arms also included a barrier membrane …”

Section: Resultsmentioning

confidence: 99%

Efficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta‐analysis

Tavelli

Chen

Barootchi

et al. 2022

Journal of Periodontology

View full text Add to dashboard Cite

Background: A large variety of biomaterials, biologics and membranes have been utilized in the past 40 years for the regenerative treatment of periodontal infrabony defects. Biologic agents have progressively gained popularity among clinicians and are routinely used for periodontal regeneration. In alignment with the goals of the American Academy of Periodontology (AAP) Best Evidence Consensus (BEC) on the use of biologic mediators in contemporary clinical practice, the aim of this sytematic review was to evaluate the effect of biologic agents, specifically autogenous blood-dervied products (ABPs), enamel matrix derivative (EMD) and recombinant human platelet-derived growth factor-BB (rhPDGF-BB), on the regenerative outcomes of infrabony defects. Methods: A detailed systematic search was conducted to identify eligible randomized control trials (RCTs) reporting the outcomes of periodontal regenerative therapy using biologics for the treatment of infrabony defects. A frequentist mixed-modeling approach to network meta-analysis (NMA), characterized by the assessment of three individual components for the treatment of an infrabony defect (the bone graft material [BG], the biologic agent, the application of a barrier membrane) was performed to evaluate and compare the relative efficacy of the different components, on the outcomes of different therapeutic modalities of periodontal regeneration. Results: A total of 153 eligible RCTs were included, with 150 studies contributing to the NMA. The quantitative analysis showed that the addition of biologic agents to bone graft significantly improves the clinical and radiographic outcomes, as compared to BG and flap procedures alone. Barrier membranes enhanced the regenerative outcomes of BG but did not provide further benefits in combination with biologics. The type of BG (autogenous, allogeneic, xenogeneic or alloplastic) and the biologic agent (EMD, platelet-rich fibrin [PRF], platelet-rich plasma [PRP] or rhPDGF-BB) played a significant role on the final outcomes of infrabony defects. Allogeneic and xenogeneic BGs exhibited statistically significantly superior clinical gain than synthetic and autogenous BGs (p < 0.05 in all the

show abstract

Section: Resultsmentioning

confidence: 99%

Efficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta‐analysis

Tavelli

Chen

Barootchi

et al. 2022

Journal of Periodontology

View full text Add to dashboard Cite

show abstract

“…Safety analyses for biologic-based treatments are based on the comparison between the rate of subjects who experienced adverse events in the test and control groups (usually a placebo or the matrix without the biologic agent). The safety of rhPDGF has been extensively shown for periodontal regeneration in intrabony and furcation defects (Nevins et al 2003; Nevins et al 2005), and its use in combination with β-TCP was approved by the US Food and Drug Administration for the treatment of periodontal osseous defects as well as for orthopedic applications (Lee et al 2017; Daniels et al 2019). The primary outcome of the present review was to assess the safety of rhPDGF when used in several clinical indications, in combination with several graft materials.…”

Section: Discussionmentioning

confidence: 99%

Recombinant Human Platelet–Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures

Tavelli

Ravidà

Barootchi

et al. 2020

JDR Clinical & Translational Research

View full text Add to dashboard Cite

Aim: The use of recombinant human platelet-derived growth factor–BB (rhPDGF) has received Food and Drug Administration approval for the treatment of periodontal and orthopedic bone defects and dermal wound healing. Many studies have investigated its regenerative potential in a variety of other oral clinical indications. The aim of this systematic review was to assess the efficacy, safety, and clinical benefit of recombinant human platelet-derived growth factor (rhPDGF) use for alveolar bone and/or soft tissue regeneration. Material and Methods: Comprehensive electronic and manual literature searches according to the PRISMA guidelines were performed to identify interventional and observational studies evaluating the regenerative applications of rhPDGF-BB. The primary outcomes were the safety, efficacy, and overall clinical benefit of rhPDGF use in oral regenerative procedures. Results: Sixty-three human clinical studies (mean ± SD follow-up period of 10.7 ± 3.3 mo) were included in the qualitative analysis. No serious adverse effects were reported in any of the 63 studies, aside from the postoperative complications routinely associated with surgical therapy. Use of rhPDGF was shown to be beneficial when combined with allografts, xenografts, and alloplasts (the latter tricalcium phosphate [β-TCP]) for the treatment of periodontal defects and gingival recession. The use of rhPDGF also led to favorable clinical outcomes when combined with allografts or xenografts for guided bone regeneration (GBR) and alveolar ridge preservation. While favorable clinical results support the use of the combination of rhPDGF plus allograft or xenograft for GBR, ARP, and sinus floor augmentation, current data support the use of rhPDGF and alloplasts (e.g., β-TCP) only in periodontal defects and gingival recession. Conclusions: Based on the clinical evidence, rhPDGF is safe and provides clinical benefits when used in combination with bone allografts, xenograft, or β-TCP for the treatment of intrabony and furcation periodontal defects and gingival recession or when used with allografts or xenograft for GBR and ARP (PROSPERO CRD42020142446). Knowledge Transfer Statement: Clinicians should be aware that rhPDGF is a safe and effective approach for the treatment of intrabony and furcation periodontal defects and gingival recession or when used with allografts or xenograft for bone regeneration and alveolar ridge preservation. With consideration of cost and patient preference, this result could lead to more appropriate therapeutic decisions.

show abstract

“…PDGF-BB is applied with bone matrix for the clinical treatment of intraosseous periodontal defects ( 19 ). PDGF-BB applied with an osteoconductive bone matrix exhibits similar or superior efficacy to autogenous bone grafts in terms of bone regeneration ( 20 ).…”

Section: Discussionmentioning

confidence: 99%

Effects of platelet‑derived growth factor‑BB on cellular morphology and cellular viability of stem cell spheroids composed of bone‑marrow‑derived stem cells

2020

View full text Add to dashboard Cite

Platelet-derived growth factor-BB (PDGF-BB) is a potent mitogenic, angiogenic and chemoattractant, and is one of the most abundant growth factors in platelet-derived products. The goal of the present study was to examine the effects of PDGF-BB on cellular morphology and cellular viability using 3D stem cell cultures. On day 1, spheroids formed well in silicon-elastomer-based concave microwells. The addition of 10 or 100 ng/ml PDGF-BB did not affect the morphology of the cell spheroids. During longer periods of incubation, the cell spheroids maintained their shape without noticeable alterations. The majority of cells in the spheroids exhibited green fluorescence when analyzed using a live/dead assay, indicative of live cells. On day 1, the Cell Counting Kit-8 (CCK-8) assay values for PDGF-BB at 0, 10 and 100 ng/ml were 0.241±0.003, 0.227±0.001 and 0.241±0.004, respectively; on day 3, the CCK-8 assay values for PDGF-BB were 0.233±0.005, 0.278±0.001 and 0.194±0.003, respectively; and on day 7, they were 0.248±0.014, 0.293±0.031 and 0.346±0.034, respectively. The 100 ng/ml group showed significantly higher values compared with the control group on day 7. Together, the results of the present study showed that the addition of 10 and 100 ng/ml PDGF-BB increased cellular viability, suggesting that PDGF-BB may be usable in cell therapy.

show abstract

Comparative Study of rhPDGF-BB Plus Equine-Derived Bone Matrix Versus rhPDGF-BB Plus β-TCP in the Treatment of Periodontal Defects

Cited by 11 publications

References 0 publications

Efficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta‐analysis

Efficacy of biologics for the treatment of periodontal infrabony defects: An American Academy of Periodontology best evidence systematic review and network meta‐analysis

Recombinant Human Platelet–Derived Growth Factor: A Systematic Review of Clinical Findings in Oral Regenerative Procedures

Effects of platelet‑derived growth factor‑BB on cellular morphology and cellular viability of stem cell spheroids composed of bone‑marrow‑derived stem cells

Contact Info

Product

Resources

About